WO2015092752A1 - Novel crystalline form of dolutegravir sodium - Google Patents
Novel crystalline form of dolutegravir sodium Download PDFInfo
- Publication number
- WO2015092752A1 WO2015092752A1 PCT/IB2014/067106 IB2014067106W WO2015092752A1 WO 2015092752 A1 WO2015092752 A1 WO 2015092752A1 IB 2014067106 W IB2014067106 W IB 2014067106W WO 2015092752 A1 WO2015092752 A1 WO 2015092752A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dolutegravir sodium
- crystalline
- sodium
- solution
- sodium form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Definitions
- the present disclosure relates to novel crystalline dolutegravir sodium Form-Mi, which is an N-methyl-2-pyrrolidone (NMP) solvate.
- NMP N-methyl-2-pyrrolidone
- Dolutegravir (DTG, GSKl 349572) is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-l infection.
- TIVICAY® tablets contain dolutegravir sodium, which is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI).
- Dolutegravir sodium is chemically known as sodium (4R, 12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4- methyl-6, 8-dioxo-3 ,4, 6, 8, 12, 12a-hexahydro-2H- pyrido [l ',2' :4,5] pyrazino[2, 1- b] [l,3]oxazin-7-olate, having the structure below:
- Formula-I PCT Publication No. WO2006116764A1 (which is hereby incorporated by reference) discloses a crystalline form of dolutegravir sodium characterized by the following X- ray powder diffraction pattern having peaks at 6.4° ⁇ 0.2°, 9.2° ⁇ 0.2°, 13.8° ⁇ 0.2°, 19.2° ⁇ 0.2° and 21.8° ⁇ 0.2° degrees 2 ⁇ .
- PCT Publication No. WO2013038407A1 discloses amorphous dolutegravir sodium characterized by the following characteristic peaks in infrared absorption spectrum at about 662 ⁇ 4, 766 ⁇ 4, 851 ⁇ 4, 886 ⁇ 4, 959 ⁇ 4, 1025 ⁇ 4, 1055 ⁇ 4, 1090 ⁇ 4, 1133 ⁇ 4, 1206 ⁇ 4, 1233 ⁇ 4, 1248 ⁇ 4, 1279 ⁇ 4, 1318 ⁇ 4, 1356 ⁇ 4, 2325 ⁇ 4 and 2348 ⁇ 4 cm "1 .
- the present disclosure provides a novel crystalline form of dolutegravir sodium. SUMMARY OF THE DISCLOSURE
- One aspect of the present disclosure provides crystalline dolutegravir sodium Form- Ml, which is an N-methyl-2-pyrrolidone (NMP) solvate, and may also be characterized by powdered X-ray diffraction pattern as shown in Figure 1.
- NMP N-methyl-2-pyrrolidone
- the present disclosure provides a process for the preparation of crystalline dolutegravir sodium Form-Ml that may be prepared by the following steps:
- Another embodiment of the present disclosure provides a process for the preparation of crystalline dolutegravir sodium Form-Mi that includes the steps of:
- Figure 1 is an X-ray powder diffractogram of crystalline dolutegravir sodium Form- Mi .
- the present invention encompasses novel crystalline form of dolutegravir sodium Form-Mi , which is an N-methyl-2-pyrrolidone solvate.
- the polymorphs of the present invention may be characterized by X-ray powder diffraction pattern.
- the X-ray diffraction patterns of the polymorphs of the disclosure were measured on BRUKER D-8 Discover powder diffractometer equipped with goniometer of ⁇ /2 ⁇ configuration and Lynx Eye detector.
- the Cu- anode X-ray tube was operated at 40 kV and 30 mA.
- the experiments were conducted over the 2 ⁇ range of 2.0°-50.0°, 0.030° step size and 0.4 seconds step time.
- the present disclosure provides crystalline dolutegravir sodium Form-Ml, characterized by powder X-ray diffraction pattern having 2 ⁇ angle positions at about 5.88, 17.57, 20.55, 21.38 and 24.77 ⁇ 0.2° degrees 2 ⁇ .
- crystalline dolutegravir sodium Form-Ml is further characterized by powder X-ray diffraction pattern having 2 ⁇ angle positions at about 6.37, 7.76, 9.54, 11.81, 12.24, 13.01, 14.55, 14.85, 15.20, 15.62, 16.10, 16.84, 17.97, 18.61, 19.07, 19.36, 19.73, 20.12, 22.23, 22.64, 22.95, 23.32, 24.09, 25.26, 25.81, 26.21, 26.67, 27.11, 27.69, 28.41, 29.65, 30.67, 31.21, 31.90, 32.55, 33.12, 34.09, 35.01, 35.44 and 36.06 ⁇ 0.2° degrees 2 ⁇ .
- the present invention relates to a process for the preparation crystalline dolutegravir sodium Form-Ml including the general steps of:
- dolutegravir sodium is dissolved in NMP at an elevated temperature and filtered the solution.
- the solution is then optionally seeding with crystalline dolutegravir sodium Form-Ml.
- the solution is then stirred, filtered, and washed with NMP before isolating the crystalline solid of dolutegravir sodium Form-Ml . If seeding is not performed, the solution may be stirred for a longer period of time to allow crystals of dolutegravir sodium Form-Ml to form slowly on their own.
- dolutegravir sodium is dissolved in NMP at an elevated temperature, which may range from about 70 to about 85 °C.
- the solution is then filtered, for example, through a Hyflo bed or through membrane filters.
- the filtered solution is stirred at a temperature of about 20-35 °C for about 12- 15 hours.
- the stir time may be reduced to 3-4 hours, if the solution is seeded with about 0.1 to 1.0% w/v crystalline dolutegravir sodium Form-Mi.
- the solution is then filtered (for example, through a Hyflo bed or membrane filter), washed with NMP, and the final crystalline dolutegravir sodium Form-Mi is isolated.
- the present invention relates to a process for the preparation crystalline dolutegravir sodium Form-Mi, including the general steps of: a) dissolving dolutegravir in NMP at ambient temperature to create a solution; b) optionally seeding with crystalline dolutegravir sodium Form-Mi ;
- dolutegravir sodium is dissolved in NMP at ambient temperatures.
- the solution may then be optionally seeded with an N- methyl-2-pyrrolidone solvate of dolutegravir sodium.
- a source of sodium cations may then be added to the solution.
- the solution is then stirred and filtered.
- the solid is then washed with NMP to isolate crystalline dolutegravir sodium Form-Mi.
- the final crystalline solid may further be dried under vacuum.
- dolutegravir sodium is dissolved in NMP at a temperature of about 20-35 °C.
- the solution is then optionally seeded with crystalline dolutegravir sodium and a sodium cation source is added.
- the solution is further stirred at about 20-35 °C for about 3-4 hours, during which Form M-l crystals grow slowly.
- the solution is then filtered.
- the resultant solid is washed with NMP to obtain the crystalline dolutegravir sodium Form-Mi.
- the final crystalline solid may optionally further be dried under vacuum at about 80 °C for about 12-15 hours.
- sodium cation source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, and an alcoholic sodium hydroxide solution, such as methanolic sodium hydroxide.
- the crystalline dolutegravir sodium Form-Mi of the present invention may be incorporated into a pharmaceutical formulation for the treatment of HIV in human patients.
- the pharmaceutical formulation may be an oral dosage form and in some embodiments a tablet.
- the tablet may include such excipients as D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
- the tablet may be coated in a film that may contain the inactive ingredients iron oxide yellow, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.
- the crystalline dolutegravir sodium Form-Mi may be administered in conjunction with other active pharmaceutical ingredients, including efavirenz, fosamprenavir, ritonavir, tipranavir, and rifampin.
- Example 1 Preparation of crystalline dolutegravir sodium Form-Ml (NMP solvate).
- Dolutegravir sodium (3 g) was dissolved in N-methyl 2-pyrrolidone (300 mL) at 75- 80 °C. The clear solution was filtered through a Hyflo bed and washed with N- methyl-2-pyrrolidone (15 mL) at 25-30 °C. The clear solution was stirred at 25-30 °C for 12-15 hours. The product obtained was filtered, washed with N-methyl-2- pyrrolidone (15 mL) at 25-30 °C and dried under vacuum at 80 °C for 12-15 hours. The resulting solid was identified as crystalline dolutegravir sodium Form-Ml, through the following analytical methods:
- Example 2 Preparation of crystalline dolutegravir sodium Form-Ml (NMP solvate).
- Dolutegravir sodium (1 g) was dissolved in N-methyl-2-pyrrolidone (100 mL) at 75- 80°C. The clear solution was filtered through a Hyflo bed and washed with N-methyl 2-pyrrolidone (5 mL) at 25-30 °C. The clear solution was seeded with N-methyl-2- pyrrolidone solvate of dolutegravir sodium Form-Ml (10 mg) and stirred at 25-30°C for 3-4 hours. The product obtained was filtered, washed with N-methyl-2- pyrrolidone (5 mL) at 25-30 °C and dried under vacuum at 80 °C for 12-15 hours. The resulting solid was identified as crystalline dolutegravir sodium Form-Ml, through the following analytical methods:
- Dolutegravir (200 mg) was dissolved in N-methyl-2-pyrrolidone (6 mL) at 25-30 °C. The clear solution was seeded with N-methyl-2-pyrrolidone solvate of dolutegravir sodium Form-Ml (2 mg) and then 0.25 N methanolic sodium hydroxide solution (2 mL) was added and stirred at 25-30 °C for 3-4 hours. The product obtained was filtered and washed with N-methyl-2-pyrrolidone (5 mL) and dried under vacuum at 80 °C for 12-15 hours. The resulting solid was identified as crystalline dolutegravir sodium Form-Ml, through the following analytical methods:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to crystalline dolutegravir sodium Form-MI, which is an N-methyl-2-pyrrolidone solvate, and a process for the preparation thereof. Formula (I):
Description
NOVEL CRYSTALLINE FORM OF DOLUTEGRAVIR SODIUM
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of the earlier filing date of Indian Provisional Patent Application No. 6001 /CHE/2013 filed on date December 20, 2013.
BACKGROUND OF THE INVENTION FIELD OF THE DISCLOSURE
The present disclosure relates to novel crystalline dolutegravir sodium Form-Mi, which is an N-methyl-2-pyrrolidone (NMP) solvate.
DESCRD7TION OF THE RELATED ART
Dolutegravir (DTG, GSKl 349572) is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-l infection.
TIVICAY® tablets contain dolutegravir sodium, which is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI). Dolutegravir sodium is chemically known as sodium (4R, 12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4- methyl-6, 8-dioxo-3 ,4, 6, 8, 12, 12a-hexahydro-2H- pyrido [l ',2' :4,5] pyrazino[2, 1- b] [l,3]oxazin-7-olate, having the structure below:
Formula-I
PCT Publication No. WO2006116764A1 (which is hereby incorporated by reference) discloses a crystalline form of dolutegravir sodium characterized by the following X- ray powder diffraction pattern having peaks at 6.4°±0.2°, 9.2°±0.2°, 13.8°±0.2°, 19.2°±0.2° and 21.8°±0.2° degrees 2Θ.
PCT Publication No. WO2013038407A1 (which is hereby incorporated by reference) discloses amorphous dolutegravir sodium characterized by the following characteristic peaks in infrared absorption spectrum at about 662±4, 766±4, 851±4, 886±4, 959±4, 1025±4, 1055±4, 1090±4, 1133±4, 1206±4, 1233±4, 1248±4, 1279±4, 1318±4, 1356±4, 2325±4 and 2348±4 cm"1.
The present disclosure provides a novel crystalline form of dolutegravir sodium. SUMMARY OF THE DISCLOSURE
One aspect of the present disclosure provides crystalline dolutegravir sodium Form- Ml, which is an N-methyl-2-pyrrolidone (NMP) solvate, and may also be characterized by powdered X-ray diffraction pattern as shown in Figure 1.
In one embodiment, the present disclosure provides a process for the preparation of crystalline dolutegravir sodium Form-Ml that may be prepared by the following steps:
a) dissolving dolutegravir sodium in NMP at elevated temperature to form a solution;
b) cooling the solution to 25-35 °C;
c) optionally seeding with crystalline dolutegravir sodium Form-Ml ; and d) isolating crystalline dolutegravir sodium Form-Ml .
Another embodiment of the present disclosure provides a process for the preparation of crystalline dolutegravir sodium Form-Mi that includes the steps of:
a) dissolving dolutegravir in NMP at ambient temperature to form a solution; b) optionally seeding with crystalline dolutegravir sodium Form-Mi ;
c) adding a sodium cation source to the solution; and
d) isolating crystalline dolutegravir sodium Form-Mi .
BRIEF DESCRIPTION OF THE FIGURES
Further aspects of the present disclosure together with additional features contributing thereto and advantages accruing there from will be apparent from the following description of embodiments of the disclosure, which are shown in the accompanying drawing figures wherein:
Figure 1 is an X-ray powder diffractogram of crystalline dolutegravir sodium Form- Mi . DETAILED DESCRIPTION OF THE DISCLOSURE
It is to be understood that the description of the present invention has been simplified to illustrate elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that may be well known.
The present invention encompasses novel crystalline form of dolutegravir sodium Form-Mi , which is an N-methyl-2-pyrrolidone solvate.
The polymorphs of the present invention may be characterized by X-ray powder diffraction pattern. Thus, the X-ray diffraction patterns of the polymorphs of the disclosure were measured on BRUKER D-8 Discover powder diffractometer equipped with goniometer of Θ/2Θ configuration and Lynx Eye detector. The Cu-
anode X-ray tube was operated at 40 kV and 30 mA. The experiments were conducted over the 2Θ range of 2.0°-50.0°, 0.030° step size and 0.4 seconds step time.
In one embodiment, the present disclosure provides crystalline dolutegravir sodium Form-Ml, characterized by powder X-ray diffraction pattern having 2Θ angle positions at about 5.88, 17.57, 20.55, 21.38 and 24.77 ± 0.2° degrees 2Θ.
According to the present disclosure, crystalline dolutegravir sodium Form-Ml is further characterized by powder X-ray diffraction pattern having 2Θ angle positions at about 6.37, 7.76, 9.54, 11.81, 12.24, 13.01, 14.55, 14.85, 15.20, 15.62, 16.10, 16.84, 17.97, 18.61, 19.07, 19.36, 19.73, 20.12, 22.23, 22.64, 22.95, 23.32, 24.09, 25.26, 25.81, 26.21, 26.67, 27.11, 27.69, 28.41, 29.65, 30.67, 31.21, 31.90, 32.55, 33.12, 34.09, 35.01, 35.44 and 36.06 ±0.2° degrees 2Θ.
In another embodiment, the present invention relates to a process for the preparation crystalline dolutegravir sodium Form-Ml including the general steps of:
a) dissolving dolutegravir sodium in NMP at elevated temperature to create a solution;
b) cooling the solution to 25-35 °C;
c) optionally seeding with crystalline dolutegravir sodium Form-Ml ; and d) isolating crystalline dolutegravir sodium Form-Ml. According to the present invention, dolutegravir sodium is dissolved in NMP at an elevated temperature and filtered the solution. The solution is then optionally seeding with crystalline dolutegravir sodium Form-Ml. The solution is then stirred, filtered, and washed with NMP before isolating the crystalline solid of dolutegravir sodium Form-Ml . If seeding is not performed, the solution may be stirred for a longer period of time to allow crystals of dolutegravir sodium Form-Ml to form slowly on their own.
In one embodiment of the present invention, dolutegravir sodium is dissolved in NMP at an elevated temperature, which may range from about 70 to about 85 °C. The solution is then filtered, for example, through a Hyflo bed or through membrane filters. The filtered solution is stirred at a temperature of about 20-35 °C for about 12- 15 hours. The stir time may be reduced to 3-4 hours, if the solution is seeded with about 0.1 to 1.0% w/v crystalline dolutegravir sodium Form-Mi. The solution is then filtered (for example, through a Hyflo bed or membrane filter), washed with NMP, and the final crystalline dolutegravir sodium Form-Mi is isolated. In an additional embodiment, the present invention relates to a process for the preparation crystalline dolutegravir sodium Form-Mi, including the general steps of: a) dissolving dolutegravir in NMP at ambient temperature to create a solution; b) optionally seeding with crystalline dolutegravir sodium Form-Mi ;
c) adding a sodium cation source to the solution; and
d) isolating crystalline dolutegravir sodium Form-Mi .
In one embodiment of the present invention, dolutegravir sodium is dissolved in NMP at ambient temperatures. The solution may then be optionally seeded with an N- methyl-2-pyrrolidone solvate of dolutegravir sodium. A source of sodium cations may then be added to the solution. The solution is then stirred and filtered. The solid is then washed with NMP to isolate crystalline dolutegravir sodium Form-Mi. The final crystalline solid may further be dried under vacuum.
Within the context of the present disclosure, dolutegravir sodium is dissolved in NMP at a temperature of about 20-35 °C. The solution is then optionally seeded with crystalline dolutegravir sodium and a sodium cation source is added. The solution is further stirred at about 20-35 °C for about 3-4 hours, during which Form M-l crystals grow slowly. The solution is then filtered. The resultant solid is washed with NMP to
obtain the crystalline dolutegravir sodium Form-Mi. The final crystalline solid may optionally further be dried under vacuum at about 80 °C for about 12-15 hours.
Within the context of the present disclosure, sodium cation source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, and an alcoholic sodium hydroxide solution, such as methanolic sodium hydroxide.
With all of the reactions disclosed above, one of skill in the art will recognize that the reaction conditions (e.g., reaction time or temperature) may be adjusted to achieve appropriate yield without undertaking undue experimentation and without departing from the scope of the present disclosure. The crystalline dolutegravir sodium Form-Mi of the present invention may be incorporated into a pharmaceutical formulation for the treatment of HIV in human patients. The pharmaceutical formulation may be an oral dosage form and in some embodiments a tablet. The tablet may include such excipients as D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet may be coated in a film that may contain the inactive ingredients iron oxide yellow, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide. The crystalline dolutegravir sodium Form-Mi may be administered in conjunction with other active pharmaceutical ingredients, including efavirenz, fosamprenavir, ritonavir, tipranavir, and rifampin.
In view of the above description and the examples below, one of ordinary skill in the art will be able to practice the invention as claimed without undue experimentation. The foregoing will be better understood with reference to the following examples that detail certain procedures for the preparation of molecules, compositions and Formulations according to the present invention. All references made to these examples are for the purposes of illustration. The following examples should not be
considered exhaustive, but merely illustrative of only a few of the many aspects and embodiments contemplated by the present disclosure.
Example 1: Preparation of crystalline dolutegravir sodium Form-Ml (NMP solvate).
Dolutegravir sodium (3 g) was dissolved in N-methyl 2-pyrrolidone (300 mL) at 75- 80 °C. The clear solution was filtered through a Hyflo bed and washed with N- methyl-2-pyrrolidone (15 mL) at 25-30 °C. The clear solution was stirred at 25-30 °C for 12-15 hours. The product obtained was filtered, washed with N-methyl-2- pyrrolidone (15 mL) at 25-30 °C and dried under vacuum at 80 °C for 12-15 hours. The resulting solid was identified as crystalline dolutegravir sodium Form-Ml, through the following analytical methods:
Yield: 80-85% (2.4 g)
PXRD: Crystalline
Purity by HPLC: 98.8 %
NMP content by GC: 13%
Example 2: Preparation of crystalline dolutegravir sodium Form-Ml (NMP solvate).
Dolutegravir sodium (1 g) was dissolved in N-methyl-2-pyrrolidone (100 mL) at 75- 80°C. The clear solution was filtered through a Hyflo bed and washed with N-methyl 2-pyrrolidone (5 mL) at 25-30 °C. The clear solution was seeded with N-methyl-2- pyrrolidone solvate of dolutegravir sodium Form-Ml (10 mg) and stirred at 25-30°C for 3-4 hours. The product obtained was filtered, washed with N-methyl-2- pyrrolidone (5 mL) at 25-30 °C and dried under vacuum at 80 °C for 12-15 hours. The resulting solid was identified as crystalline dolutegravir sodium Form-Ml, through the following analytical methods:
Yield: 80-85% (0.8 g)
PXRD: Crystalline
Purity by HPLC: 99.03 %
NMP content by GC: 13% Example 3: Preparation of crystalline dolutegravir sodium Form-Ml (NMP solvate).
Dolutegravir (200 mg) was dissolved in N-methyl-2-pyrrolidone (6 mL) at 25-30 °C. The clear solution was seeded with N-methyl-2-pyrrolidone solvate of dolutegravir sodium Form-Ml (2 mg) and then 0.25 N methanolic sodium hydroxide solution (2 mL) was added and stirred at 25-30 °C for 3-4 hours. The product obtained was filtered and washed with N-methyl-2-pyrrolidone (5 mL) and dried under vacuum at 80 °C for 12-15 hours. The resulting solid was identified as crystalline dolutegravir sodium Form-Ml, through the following analytical methods:
Yield: 75% (160 mg)
PXRD: Crystalline
Purity by HPLC: 99.66%
Although the invention has been described in terms of particular embodiments in an application, one of ordinary skill in the art, in light of the teachings herein, can generate additional embodiments and modifications without departing from the spirit of, or exceeding the scope of, the claimed invention. Accordingly, it is understood that the descriptions herein are proffered only to facilitate comprehension of the invention and should not be construed to limit the scope thereof.
Claims
1. A crystalline dolutegravir sodium Form-Ml , which has a powder X-ray diffraction pattern having 2Θ angle of significant peaks at about 5.88, 17.57, 20.55, 21.38 and 24.77 ±0.2° degrees 2Θ.
2. A crystalline dolutegravir sodium Form-Ml, according to claim 1 which has a powder X-ray diffraction pattern having 2Θ angle of significant peaks at about 6.37, 7.76, 9.54, 11.81, 12.24, 13.01, 14.55, 14.85, 15.20, 15.62, 16.10, 16.84, 17.97, 18.61, 19.07, 19.36, 19.73, 20.12, 22.23, 22.64, 22.95, 23.32, 24.09, 25.26, 25.81, 26.21, 26.67, 27.11, 27.69, 28.41, 29.65, 30.67, 31.21, 31.90, 32.55, 33.12, 34.09, 35.01, 35.44 and 36.06 ±0.2° degrees 2Θ.
3. A crystalline dolutegravir sodium Form-Ml according to claims 1-2, wherein said crystalline dolutegravir sodium Form-Ml is an N-methyl-2-pyrrolidone solvate.
4. A crystalline dolutegravir sodium Form-Ml, which has a powder X-ray diffraction pattern as shown in Figure 1.
5. A process for the preparation of crystalline dolutegravir sodium Form-Ml comprising the steps of:
a) dissolving dolutegravir sodium in N-methyl-2-pyrrolidone at elevated temperature;
b) cooling the solution of step (a) to 25-35 °C; and
c) isolating crystalline dolutegravir sodium Form-Mi .
6. The processes of claim 5, further comprising seeding the solution with crystalline dolutegravir sodium Form-Mi after said dissolving step.
7. A process for the preparation of crystalline dolutegravir sodium Form-Mi comprising the steps of:
a) dissolving dolutegravir in N-methyl-2-pyrrolidone at ambient temperature to form a solution;
b) adding a sodium cation source to the solution; and
c) isolating crystalline dolutegravir sodium Form-Mi .
8. The processes of claim 7, further comprising seeding the solution with crystalline dolutegravir sodium Form-Mi after said dissolving step.
9. The process of claim 7, wherein said sodium cation source is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, and an alcoholic sodium hydroxide solution, such as methanolic sodium hydroxide.
10. The process of claim 5, wherein said isolating step includes washing, filtering, or vacuum drying.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6001CH2013 | 2013-12-20 | ||
| IN6001/CHE/2013 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015092752A1 true WO2015092752A1 (en) | 2015-06-25 |
Family
ID=52462352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2014/067106 Ceased WO2015092752A1 (en) | 2013-12-20 | 2014-12-19 | Novel crystalline form of dolutegravir sodium |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015092752A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017029642A2 (en) | 2015-08-19 | 2017-02-23 | Laurus Labs Private Limited | Novel polymorphs of dolutegravir and salts thereof |
| WO2017046131A1 (en) * | 2015-09-15 | 2017-03-23 | Ratiopharm Gmbh | Processes for preparing solid state forms of dolutegravir sodium |
| WO2017208105A1 (en) | 2016-05-30 | 2017-12-07 | Lupin Limited | Novel crystalline form of dolutegravir sodium |
| WO2019048808A1 (en) | 2017-09-07 | 2019-03-14 | Cipla Limited | New polymorphs of dolutegravir sodium |
| EP3177629B1 (en) * | 2014-07-29 | 2020-01-29 | LEK Pharmaceuticals d.d. | Novel hydrates of dolutegravir sodium |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006116764A1 (en) | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| WO2010068253A1 (en) * | 2008-12-11 | 2010-06-17 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| WO2013038407A1 (en) | 2011-09-14 | 2013-03-21 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
-
2014
- 2014-12-19 WO PCT/IB2014/067106 patent/WO2015092752A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006116764A1 (en) | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| WO2010068253A1 (en) * | 2008-12-11 | 2010-06-17 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| WO2013038407A1 (en) | 2011-09-14 | 2013-03-21 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3177629B1 (en) * | 2014-07-29 | 2020-01-29 | LEK Pharmaceuticals d.d. | Novel hydrates of dolutegravir sodium |
| WO2017029642A2 (en) | 2015-08-19 | 2017-02-23 | Laurus Labs Private Limited | Novel polymorphs of dolutegravir and salts thereof |
| US10597404B2 (en) | 2015-08-19 | 2020-03-24 | Laurus Labs Ltd. | Polymorphs of dolutegravir and salts thereof |
| US10647729B1 (en) | 2015-08-19 | 2020-05-12 | Laurus Labs Limited | Polymorphs of dolutegravir and salts thereof |
| US10654872B1 (en) | 2015-08-19 | 2020-05-19 | Laurus Labs Limited | Polymorphs of dolutegravir and salts thereof |
| WO2017046131A1 (en) * | 2015-09-15 | 2017-03-23 | Ratiopharm Gmbh | Processes for preparing solid state forms of dolutegravir sodium |
| WO2017208105A1 (en) | 2016-05-30 | 2017-12-07 | Lupin Limited | Novel crystalline form of dolutegravir sodium |
| WO2019048808A1 (en) | 2017-09-07 | 2019-03-14 | Cipla Limited | New polymorphs of dolutegravir sodium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2938103C (en) | Crystalline forms of dolutegravir sodium | |
| WO2015092752A1 (en) | Novel crystalline form of dolutegravir sodium | |
| EA020489B1 (en) | Modulators of pharmacokinetic properties of therapeutics | |
| WO2016038532A1 (en) | Amorphous treprostinil diethanolamine | |
| KR102737283B1 (en) | Method for preparing ridinilazole and its crystalline form | |
| EP3145913A1 (en) | Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base | |
| CN105189513A (en) | Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate | |
| WO2015139591A1 (en) | Crystalline form of dolutegravir sodium salt and preparation method therefor | |
| WO2016135755A1 (en) | Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast | |
| JP5057986B2 (en) | Organic compounds | |
| CN111153964B (en) | Carfilzomib crystal form, preparation method and application thereof | |
| DK2041083T3 (en) | Methods for the preparation of zofenopril calcium | |
| US11466031B2 (en) | Polymorphic forms of bictegravir and its sodium salt | |
| EP2714683A2 (en) | Amorphous ritonavir co-precipitated | |
| TW201722950A (en) | Salt of morpholine derivative and its crystal form, manufacturing method thereof, pharmaceutical composition and use thereof | |
| ES2969437T3 (en) | Novel polymorphs of dolutegravir and its salts | |
| JP4516962B2 (en) | Carbostyryl derivative amine salt | |
| CN101981004B (en) | crystal form | |
| EP3102565B1 (en) | Processes for the preparation of intermediates of raltegravir | |
| KR102100357B1 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
| WO2014013505A2 (en) | Amorphous vildagliptin | |
| CA2829186A1 (en) | Amorphous form of lopinavir and ritonavir mixture | |
| HK40016752A (en) | Crystalline form of gcc-4401c and pharmaceutical composition comprising the crystalline form | |
| HK1236514A1 (en) | Crystalline form of gcc-4401c and pharmaceutical composition comprising same | |
| WO2014102832A2 (en) | Saxagliptin hydrochloride solid dispersion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14835504 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14835504 Country of ref document: EP Kind code of ref document: A1 |